Meeting
2024 ASCO Annual Meeting
Characterization of T-cell receptor repertoire and correlation with tumor mutational landscape in lung cancer.
Authors
Wei Guo
HaploX Biotechnology, Shenzhen, China
Wei Guo , Huaichao Luo , Linfeng Dong , Yanqing Zhou , Zuoquan Yang , Jialin Zhang , Shuxiong Zhou , Hui Li , Yuanyuan Liu , Dongsheng Wang , Shifu Chen
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Immunotherapy
Track
Developmental Therapeutics—Immunotherapy
Sub Track
Immunobiology
Clinical Trial Registration Number
ChiCTR2200055761
Citation
J Clin Oncol 42, 2024 (suppl 16; abstr 2577)
DOI
10.1200/JCO.2024.42.16_suppl.2577
Abstract #
2577
Poster Bd #
56
Abstract Disclosures
Similar Posters
Poster
2017 ASCO Annual Meeting
Bim and soluble PD-L1 (sPD-L1) as predictive biomarkers of response to anti-PD-1 therapy in patients with melanoma and lung carcinoma.
First Author: Roxana Stefania Dronca
Poster
2024 ASCO Breakthrough
Effect of heterozygosity loss of HLA-I on immune evasion and promotion of non-small cell lung cancer brain metastasis and immunotherapy resistance.
First Author: Jiefei Han
Poster
2023 ASCO Breakthrough
Identification of intratumoral and peripheral T-cell receptor (TCR) repertoire features associated with acquired (Ar) and primary (Pr) resistance to immune checkpoint inhibitors (ICI).
First Author: Sofia Genta
Poster
2023 ASCO Annual Meeting
Pathway enrichment analysis in tumors with high mutation burdens and interferon-γ signature expression: A pancancer analysis.
First Author: Xuanyi Li